Atlas Trials

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Clinical trial NCT02752685 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02752685
Sponsor
NYU Langone Health
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2016-06-01
Primary completion
2022-12-29
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.